Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

The new entity will operate under the brand of Orano Med, a subsidiary of Orano Group. Sanofi already has a relationship with Orano Med. Last month, the Paris-based pharmaceutical giant licensed ...

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi ...

Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024. Sanofi and Orano Med, a subsidiary of the ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the ...

Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a ...